South Korea’s NVP Healthcare banks on gut-liver probiotic for global growth


This comes after successful patent registration in its domestic market and various countries, namely Japan, China, Russia, the US, Australia, Canada, India, Mexico and Philippines.

The patent relates to Lactobacillus plantarum LC27 ​(L. plantarum ​LC27) and Bifidobacterium longum LC67 ​(B. longum​ LC67), lactic acid bacteria strains that have been found to be effective in preventing and treating liver diseases such as hepatitis, fatty liver, and cirrhosis.

Using its proprietary DuoBiome technology, NVP Healthcare developed a complex probiotic called NVP-1702, which consists of B. longum​ LC67 isolated from the intestines of healthy Koreans and L. plantarum ​LC27 isolated from kimchi.

NVP-1702 was approved by Korea’s Ministry of Food and Drug Safety (MFDS) as a functional ingredient in July last year. It is the first and only probiotic recognised by the authority for the claim of improving both gut and liver function.

“After the patent registration has been completed in Europe, which is the home of lactobacillus, it will lay the foundation for our global expansion,” ​the firm said.

In addition, the company has conducted clinical trials to confirm the effectiveness of NVP-1702 in improving alcoholic liver damage.

Fatty liver, a common manifestation of liver damage, is caused by various factors, including obesity, stress, and excessive drinking.

According to several recent studies, intestinal microbial imbalance has also been pointed out as a cause of liver damage.

“In the intestines of people with fatty liver, endotoxins, including lipopolysaccharides (LPS), increase intestinal permeability. This reportedly leads to liver damage as endotoxins move directly to the liver through the portal vein.”


Leave a Reply

Your email address will not be published. Required fields are marked *